Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 4Other hematologic neoplasm 3Lymphoid 3Thoracic 2Sarcoma 1Plasma cell 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Lymphoma, Non-Hodgkin 21Leukemia, Lymphocytic, Chronic, B-Cell 14Lymphoma 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, Follicular 9Leukemia, Myeloid, Acute 9Hodgkin Disease 7Lymphoma, Mantle-Cell 6Lymphoma, Large B-Cell, Diffuse 6Leukemia 6Myelodysplastic Syndromes 5Multiple Myeloma 5Lymphoma, B-Cell, Marginal Zone 5Lymphoma, B-Cell 5Hematologic Neoplasms 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Burkitt Lymphoma 4Stomach Neoplasms 3Recurrence 3Lymphoma, Large-Cell, Immunoblastic 3Colorectal Neoplasms 3Waldenstrom Macroglobulinemia 2Neoplasms 2Neoplasm Metastasis 2Melanoma 2Leukemia, Myelomonocytic, Juvenile 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Thrombocythemia, Essential 1

Interventions

Cyclophosphamide 100Rituximab 82fludarabine phosphate 46Peripheral Blood Stem Cell Transplantation 45fludarabine 43Lenalidomide 35Filgrastim 33Methotrexate 32Cytarabine 32Busulfan 32Etoposide 31venetoclax 30Cyclosporine 30Dexamethasone 29Radiotherapy 28Mycophenolic Acid 28Melphalan 28Bendamustine Hydrochloride 25Antilymphocyte Serum 25Vincristine 24Gemcitabine 24ibrutinib 22Whole-Body Irradiation 22Doxorubicin 20Tacrolimus 19Methylprednisolone 18Bortezomib 18Brentuximab Vedotin 16pembrolizumab 15Prednisone 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recurrence × Interleukin-2 × Lymphoid × Clear all
NCT05883449 2025-08-20

LuminICE-203

Affimed GmbH

Phase 2 Terminated
25 enrolled 21 charts
Lymphoid

Hodgkin Disease, Recurrence, Lymphoma, T-Cell, Peripheral

NCT04887259 2025-01-27

Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML

Lava Therapeutics

Phase 1 Terminated
16 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

NCT00070187 2013-10-17

Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

Children's Oncology Group

Phase 2/3 Completed
24 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡